Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
暂无分享,去创建一个
John M Lachin | Christoph Wanner | B. Zinman | C. Wanner | D. Fitchett | J. Lachin | S. Inzucchi | U. Broedl | M. von Eynatten | O. Johansen | M. Mattheus | Silvio E Inzucchi | Bernard Zinman | Uli C Broedl | David Fitchett | Maximilian von Eynatten | Michaela Mattheus | Odd Erik Johansen | Hans J Woerle | H. Woerle
[1] K. Khunti,et al. Relevance of positive cardiovascular outcome trial results in clinical practice: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes (ACROSS T2D) , 2017, Therapeutics and clinical risk management.
[2] R. Unwin,et al. A more tubulocentric view of diabetic kidney disease , 2017, Journal of Nephrology.
[3] M. Wakisaka,et al. Sodium glucose cotransporter 2 in mesangial cells and retinal pericytes and its implications for diabetic nephropathy and retinopathy , 2017, Glycobiology.
[4] D. Fitchett,et al. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications. , 2016, Circulation.
[5] M. Wakisaka,et al. Sodium Glucose Cotransporter 2 (SGLT2) Plays as a Physiological Glucose Sensor and Regulates Cellular Contractility in Rat Mesangial Cells , 2016, PloS one.
[6] A. Tsapas,et al. Empagliflozin , Cardiovascular Outcomes , and Mortality in Type 2 Diabetes , 2015 .
[7] C. Cannon,et al. Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes , 2015, Diabetes, obesity & metabolism.
[8] J. Rosenstock,et al. Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78‐week randomized, double‐blind, placebo‐controlled trial , 2015, Diabetes, obesity & metabolism.
[9] D. Cherney,et al. Sodium–glucose cotransporter-2 inhibition and the potential for renal protection in diabetic nephropathy , 2015, Current opinion in nephrology and hypertension.
[10] B. Kasiske,et al. Diabetic Kidney Disease– A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO) , 2014, Kidney international.
[11] R. Karen,et al. Diabetic kidney disease , 2015, Nature Reviews Disease Primers.
[12] U. Broedl,et al. Sodium glucose cotransport-2 inhibition and intrarenal RAS activity in people with type 1 diabetes. , 2014, Kidney international.
[13] M. Woodward,et al. Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. , 2014, The New England journal of medicine.
[14] U. Broedl,et al. Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration , 2014, Diabetologia.
[15] I. Tikkanen,et al. Empagliflozin Reduces Blood Pressure in Patients With Type 2 Diabetes and Hypertension , 2014, Diabetes Care.
[16] B. Zinman,et al. Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™) , 2014, Cardiovascular Diabetology.
[17] J. Rosenstock,et al. Improved Glucose Control With Weight Loss, Lower Insulin Doses, and No Increased Hypoglycemia With Empagliflozin Added to Titrated Multiple Daily Injections of Insulin in Obese Inadequately Controlled Type 2 Diabetes , 2014, Diabetes Care.
[18] J. Tank,et al. Complexity of Impaired Parasympathetic Heart Rate Regulation in Diabetes , 2014, Diabetes.
[19] H. Häring,et al. Empagliflozin as Add-On to Metformin in Patients With Type 2 Diabetes: A 24-Week, Randomized, Double-Blind, Placebo-Controlled Trial , 2014, Diabetes Care.
[20] A. Mithal,et al. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. , 2014, The lancet. Diabetes & endocrinology.
[21] U. Broedl,et al. Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus , 2014, Circulation.
[22] C. Kovacs,et al. Empagliflozin improves glycaemic and weight control as add‐on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24‐week, randomized, placebo‐controlled trial , 2014, Diabetes, obesity & metabolism.
[23] H. Heerspink,et al. The effect of RAAS blockade on the progression of diabetic nephropathy , 2014, Nature Reviews Nephrology.
[24] U. Broedl,et al. The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus , 2014, Cardiovascular Diabetology.
[25] H. Koepsell,et al. SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice. , 2014, American journal of physiology. Renal physiology.
[26] M. Roden,et al. Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial. , 2013, The lancet. Diabetes & endocrinology.
[27] H. Häring,et al. Empagliflozin as Add-on to Metformin Plus Sulfonylurea in Patients With Type 2 Diabetes , 2013, Diabetes Care.
[28] R. DeFronzo,et al. Novel Hypothesis to Explain Why SGLT2 Inhibitors Inhibit Only 30–50% of Filtered Glucose Load in Humans , 2013, Diabetes.
[29] T. Heise,et al. Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes , 2013, Diabetes, obesity & metabolism.
[30] M. Woodward,et al. Intensive glucose control improves kidney outcomes in patients with type 2 diabetes. , 2013, Kidney international.
[31] B. Kestenbaum,et al. Kidney disease and increased mortality risk in type 2 diabetes. , 2013, Journal of the American Society of Nephrology : JASN.
[32] Nish Chaturvedi,et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. , 2012, The New England journal of medicine.
[33] H. Krumholz,et al. Role of intensive glucose control in development of renal end points in type 2 diabetes mellitus: systematic review and meta-analysis intensive glucose control in type 2 diabetes. , 2012, Archives of internal medicine.
[34] Merlin C. Thomas,et al. An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function. , 2011, Kidney international.
[35] Patrick J Heagerty,et al. Temporal trends in the prevalence of diabetic kidney disease in the United States. , 2011, JAMA.
[36] D. Loo,et al. Biology of human sodium glucose transporters. , 2011, Physiological reviews.
[37] Rodica Pop-Busui,et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial , 2010, The Lancet.
[38] J. Danesh,et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. , 2010, Lancet.
[39] The Emerging Risk Factors Collaboration. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies , 2010, The Lancet.
[40] C. Schmid,et al. A new equation to estimate glomerular filtration rate. , 2009, Annals of internal medicine.
[41] Grant D. Huang,et al. Glucose control and vascular complications in veterans with type 2 diabetes. , 2009, The New England journal of medicine.
[42] Diederick Grobbee,et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. , 2008, The New England journal of medicine.
[43] H. Kobori,et al. The Intrarenal Renin-Angiotensin System: From Physiology to the Pathobiology of Hypertension and Kidney Disease , 2007, Pharmacological Reviews.
[44] R. Spiro,et al. Glucose entry into rat mesangial cells is mediated by both Na+-coupled and facilitative transporters , 1995, Diabetologia.
[45] Oluf Pedersen,et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. , 2003, The New England journal of medicine.
[46] B. Ballermann,et al. Renal considerations in angiotensin converting enzyme inhibitor therapy: a statement for healthcare professionals from the Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association. , 2001, Circulation.
[47] E. Lewis,et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. , 2001, The New England journal of medicine.
[48] Teven,et al. EFFECTS OF LOSARTAN ON RENAL AND CARDIOVASCULAR OUTCOMES IN TYPE 2 DIABETES AND NEPHROPATHY EFFECTS OF LOSARTAN ON RENAL AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES AND NEPHROPATHY , 2001 .
[49] John S Yudkin,et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study , 2000, BMJ : British Medical Journal.
[50] A. Levey,et al. A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation , 1999, Annals of Internal Medicine.
[51] M. Fujishima,et al. Normalization of glucose entry under the high glucose condition by phlorizin attenuates the high glucose-induced morphological and functional changes of cultured bovine retinal pericytes. , 1999, Biochimica et biophysica acta.
[52] Uk-Prospective-Diabetes-Study-Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) , 1998, The Lancet.
[53] D. Vaughan,et al. Angiotensin-converting enzyme inhibitors. , 1998, Circulation.